Tags

Type your tag names separated by a space and hit enter

Protein profiling in pancreatic juice for detection of intraductal papillary mucinous neoplasm of the pancreas.
Hepatogastroenterology. 2008 Sep-Oct; 55(86-87):1824-9.H

Abstract

BACKGROUND/AIMS

Malignant intraductal papillary mucinous neoplasm of the pancreas (IPMN) has a very poor prognosis, and there is no useful biomarker for an early diagnosis at present. A biomarker is expected to allow an early diagnosis of IPMNs and consequently lead to an improvement of the patients' prognosis. Recent advances in proteomic analysis are remarkable; therefore we explored novel biomarkers for IPMN using Surface-Enhanced Laser Desorption and Ionization (SELDI) Mass Spectrometry.

METHODOLOGY

We collected pancreatic juice samples from 33 patients with IPMNs, 54 patients with pancreatic ductal carcinoma, and 31 with chronic pancreatitis. We analyzed the pancreatic juice samples using a SELDI ProteinChip system (Ciphergen Biosystems, Fremont, CA).

RESULTS

We identified a 6240-Da peak whose expression in pancreatic juice from patients with IPMNs was significantly higher compared with that in other pancreatic diseases (P<0.01). This 6240-Da protein was partially purified and was identified as pancreatic secretory trypsin inhibitor (PSTI) by amino acid sequencing. The pancreatic juice PSTI levels, as measured by radioimmunoassay, were significantly higher in the IPMN group than in the other groups (P<0.001). When the diagnostic cutoff value of PSTI in pancreatic juice was set at 25000 ng/mL, the positive predictive value, negative predictive value, sensitivity, and specificity were respectively 89%, 83%, 48%, and 98%.

CONCLUSIONS

PSTI levels of pancreatic juice in patients with IPMN were significantly higher than those in patients with other pancreatic diseases. The PSTI level in pancreatic juice may be useful for the diagnosis of IPMN.

Authors+Show Affiliations

Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. chiba0500@yahoo.co.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19102401

Citation

Shirai, Yoshihiko, et al. "Protein Profiling in Pancreatic Juice for Detection of Intraductal Papillary Mucinous Neoplasm of the Pancreas." Hepato-gastroenterology, vol. 55, no. 86-87, 2008, pp. 1824-9.
Shirai Y, Sogawa K, Yamaguchi T, et al. Protein profiling in pancreatic juice for detection of intraductal papillary mucinous neoplasm of the pancreas. Hepatogastroenterology. 2008;55(86-87):1824-9.
Shirai, Y., Sogawa, K., Yamaguchi, T., Sudo, K., Nakagawa, A., Sakai, Y., Ishihara, T., Sunaga, M., Nezu, M., Tomonaga, T., Miyazaki, M., Saisho, H., & Nomura, F. (2008). Protein profiling in pancreatic juice for detection of intraductal papillary mucinous neoplasm of the pancreas. Hepato-gastroenterology, 55(86-87), 1824-9.
Shirai Y, et al. Protein Profiling in Pancreatic Juice for Detection of Intraductal Papillary Mucinous Neoplasm of the Pancreas. Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1824-9. PubMed PMID: 19102401.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Protein profiling in pancreatic juice for detection of intraductal papillary mucinous neoplasm of the pancreas. AU - Shirai,Yoshihiko, AU - Sogawa,Kazuyuki, AU - Yamaguchi,Taketo, AU - Sudo,Kentaro, AU - Nakagawa,Akihiko, AU - Sakai,Yuji, AU - Ishihara,Takeshi, AU - Sunaga,Masahiko, AU - Nezu,Masahiko, AU - Tomonaga,Takeshi, AU - Miyazaki,Masaru, AU - Saisho,Hiromitsu, AU - Nomura,Fumio, PY - 2008/12/24/entrez PY - 2008/12/24/pubmed PY - 2009/1/28/medline SP - 1824 EP - 9 JF - Hepato-gastroenterology JO - Hepatogastroenterology VL - 55 IS - 86-87 N2 - BACKGROUND/AIMS: Malignant intraductal papillary mucinous neoplasm of the pancreas (IPMN) has a very poor prognosis, and there is no useful biomarker for an early diagnosis at present. A biomarker is expected to allow an early diagnosis of IPMNs and consequently lead to an improvement of the patients' prognosis. Recent advances in proteomic analysis are remarkable; therefore we explored novel biomarkers for IPMN using Surface-Enhanced Laser Desorption and Ionization (SELDI) Mass Spectrometry. METHODOLOGY: We collected pancreatic juice samples from 33 patients with IPMNs, 54 patients with pancreatic ductal carcinoma, and 31 with chronic pancreatitis. We analyzed the pancreatic juice samples using a SELDI ProteinChip system (Ciphergen Biosystems, Fremont, CA). RESULTS: We identified a 6240-Da peak whose expression in pancreatic juice from patients with IPMNs was significantly higher compared with that in other pancreatic diseases (P<0.01). This 6240-Da protein was partially purified and was identified as pancreatic secretory trypsin inhibitor (PSTI) by amino acid sequencing. The pancreatic juice PSTI levels, as measured by radioimmunoassay, were significantly higher in the IPMN group than in the other groups (P<0.001). When the diagnostic cutoff value of PSTI in pancreatic juice was set at 25000 ng/mL, the positive predictive value, negative predictive value, sensitivity, and specificity were respectively 89%, 83%, 48%, and 98%. CONCLUSIONS: PSTI levels of pancreatic juice in patients with IPMN were significantly higher than those in patients with other pancreatic diseases. The PSTI level in pancreatic juice may be useful for the diagnosis of IPMN. SN - 0172-6390 UR - https://www.unboundmedicine.com/medline/citation/19102401/Protein_profiling_in_pancreatic_juice_for_detection_of_intraductal_papillary_mucinous_neoplasm_of_the_pancreas_ L2 - https://medlineplus.gov/pancreaticcancer.html DB - PRIME DP - Unbound Medicine ER -